Production in Escherichia coli of recombinant COVID-19 spike protein fragments fused to CRM197.

ABSTRACT: During 2020, the COVID-19 pandemic affected almost 10⁸ individuals. Quite a number of vaccines against COVID-19 were therefore developed, and a few recently received authorization for emergency use. Overall, these vaccines target specific viral proteins by antibodies whose synthesis is directly elicited or indirectly triggered by nucleic acids coding for the desired targets. Among these targets, the receptor binding domain (RBD) of COVID-19 spike protein (SP) does frequently occur in the repertoire of candidate vaccines. However, the immunogenicity of RBD per se is limited by its low molecular mass, and by a structural rearrangement of full-length SP accompanied by the detachment of RBD. Here we show that the RBD of COVID-19 SP can be conveniently produced in Escherichia coli wh

SUBMITTER: Bellone ML 

PROVIDER: S-EPMC8057744 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature